THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

WEIGHT & METABOLIC HEALTH / PRACTITIONER-GUIDED

GLP-1–based medications

EvidenceEvidence in context
Strong human evidence for approved products and indications; individual benefits and risks vary.
RegulatoryProduct-specific
Prescription required; product-specific FDA indications
Corrections & editorial standards
FDA-approved medications may be considered for specific diabetes or chronic weight-management indications after clinical evaluation.Create account & prepare for review Florida pilot planned · A prescription is never guaranteed.
Unbranded injector pen and vial representing GLP-1 treatment
Metabolic treatment guide
WHAT IT MAY HELP WITH

Can support clinically meaningful weight loss and metabolic improvement for eligible patients while nutrition, activity and muscle preservation remain active parts of care.

EVIDENCE

Strong human evidence for approved products and indications; individual benefits and risks vary.

STATUS

Prescription required; product-specific FDA indications

WHO MAY BE CONSIDERED

Eligibility starts with your complete health context.

  • ✓Eligibility is established from medical history and objective measures
  • ✓Contraindications and interacting conditions are reviewed
  • ✓Follow-up, nutrition and side-effect monitoring are available

WHAT A PRACTITIONER REVIEWS

The information that shapes the decision.

  • Weight history and prior attempts
  • Diabetes, pancreatic, gallbladder and GI history
  • Current medications, pregnancy plans and relevant laboratory context

IMPORTANT SAFETY INFORMATION

Reasons treatment may not be appropriate.

  • !No prescription is guaranteed.
  • !Compounded products are not FDA-approved and are not interchangeable with approved drugs.
  • !FDA now requires class-wide labeling about a potential increased risk of rare NAION; sudden, painless vision loss or other new one-eye visual changes require immediate clinician contact.
  • !Severe or persistent symptoms require prompt clinician contact.

ORIGINAL SOURCES

Review the evidence behind the option.

FDA: GLP-1 labeling change for potential NAION riskFDA: concerns with unapproved GLP-1 drugsFDA Drugs@FDA

OTHER PRESCRIPTION OPTIONS

HormonesTestosterone therapyView details →HormonesMenopause hormone therapyView details →Sexual healthPDE5 inhibitors (ED meds)View details →

YOUR NEXT STEP

Ready for a clinician-led plan?

Clinical review determines the appropriate next step. No treatment is guaranteed.

THE CARE PATH

  1. We order your labs

  2. A licensed clinician reviews results and recommends a plan

  3. Rx sent directly to you when appropriate

Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.

Start your lab reviewExplore free educational tools